Sopharma AD-Sofia (WAR:SPH) PEG Ratio: N/A (As of Jul. 04, 2026)


WAR:SPH Sopharma AD-Sofia WAR:SPH
66 GF Score
Price zł7.70
GF Value zł13.50
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Sopharma AD-Sofia's PE Ratio without NRI is 9.09. Sopharma AD-Sofia's 5-Year EBITDA growth rate is -1.10%. Therefore, Sopharma AD-Sofia's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Sopharma AD-Sofia's PEG Ratio or its related term are showing as below:


During the past 13 years, Sopharma AD-Sofia's highest PEG Ratio was 36.70. The lowest was 0.56. And the median was 1.71.


WAR:SPH's PEG Ratio is not ranked *
in the Medical Distribution industry.
Industry Median: 1.865
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Sopharma AD-Sofia  (WAR:SPH) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Sopharma AD-Sofia PEG Ratio Related Terms


Sopharma AD-Sofia PEG Ratio Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia PEG Ratio Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.44 0.94 0.82 1.89 0.00

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.91 3.41 1.46 0.00 0.00

WAR:SPH vs MCK, CAH, COR: PEG Ratio Comparison

For the Medical Distribution subindustry, Sopharma AD-Sofia's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma AD-Sofia PEG Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's PEG Ratio falls into.


WAR:SPH
66GF Score
Sopharma AD-Sofia WAR:SPH
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Sopharma AD-Sofia's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=9.0909090909091/-1.10
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of zł7.70 is trading 43% below its estimated GF Value™ of zł13.50. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for WAR:SPH:

  • PEG Ratio: N/A
  • GF Value™: zł13.50 vs. price of zł7.70 (43% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sopharma AD-Sofia Business Description

Other Exchanges 3JR:GermanySFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score

Get the complete analysis for WAR:SPH

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.70
Price
zł13.50
GF Value